MRNA Moderna Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRNA

Price (delayed)

$79.76

Market cap

$31.65B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.15

Enterprise value

$30.99B

?
Relative Growth: Rel. Growth: 17
Relative Strength: Rel. Strength: 96
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 17

Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert ...

Highlights
MRNA's revenue is down by 30% year-on-year but it is up by 14% since the previous quarter
The net income has contracted by 13% from the previous quarter but it has grown by 4.9% YoY
The debt has surged by 78% year-on-year
MRNA's gross profit has plunged by 71% YoY and by 54% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.modernatx.com/
Peers: MRK NVS JNJ ARWR

Key stats

What are the main financial stats of MRNA

MRNA stock price

How has the Moderna stock price performed over time
Intraday
10.01%
1 week
33.49%
1 month
74.76%
1 year
163.41%
YTD
170.46%
QTD
13.89%

Financial performance

How have Moderna's revenue and profit performed over time
Revenue
$2.23B
Gross profit
$492M
Operating income
-$3.41B
Net income
-$3.19B
Gross margin
22.1%
Net margin
-143.6%
MRNA's gross profit has plunged by 71% YoY and by 54% from the previous quarter
The gross margin has plunged by 60% from the previous quarter and by 59% YoY
The net margin has declined by 36% year-on-year
Moderna's operating margin has decreased by 31% YoY but it has increased by 3% QoQ

Price vs fundamentals

How does MRNA's price correlate with its fundamentals

Growth

What is Moderna's growth rate over time

Valuation

What is Moderna stock price valuation
MRNA P/E details
P/E
N/A
P/B
4.25
P/S
14.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.93
The company's EPS fell by 12% QoQ but it rose by 7% YoY
MRNA's P/B is 166% above its last 4 quarters average of 1.6 and 21% above its 5-year quarterly average of 3.5
The equity is down by 26% YoY and by 14% QoQ
The stock's P/S is 167% above its 5-year quarterly average of 5.3 and 148% above its last 4 quarters average of 5.7
MRNA's revenue is down by 30% year-on-year but it is up by 14% since the previous quarter

Efficiency

How efficient is Moderna business performance
The company's return on sales fell by 32% YoY
MRNA's return on equity is down by 22% since the previous quarter and by 22% year-on-year
The ROIC has contracted by 19% from the previous quarter and by 14% YoY
Moderna's ROA has decreased by 16% from the previous quarter and by 16% YoY

Dividends

What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRNA.

Financial health

How did Moderna financials performed over time
Moderna's total assets is 182% more than its total liabilities
Moderna's total liabilities has surged by 55% YoY and by 11% QoQ
The current ratio has declined by 43% year-on-year and by 27% since the previous quarter
The debt is 83% smaller than the equity
The company's debt to equity has surged by 143% YoY and by 13% QoQ
The debt has surged by 78% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.